Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-14 |
2024-03 |
-0.3 |
N/A |
N/A |
N/A |
2024-04-01 |
2023-12 |
-0.62 |
-0.64 |
-0.02 |
-3.23% |
2023-11-09 |
2023-09 |
-0.76 |
-0.61 |
0.15 |
19.74% |
2023-11-09 |
2023-09 |
-0.76 |
N/A |
N/A |
N/A |
2023-08-14 |
2023-06 |
-0.84 |
-0.7 |
0.14 |
16.67% |
2023-08-14 |
2023-06 |
-0.84 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-05-29 |
Chardan Capital |
Upgrade |
Buy |
Buy |
2023-05-10 |
Chardan Capital |
Upgrade |
|
Buy |
2023-01-26 |
Morgan Stanley |
Upgrade |
|
Overweight |
2022-12-20 |
Chardan Capital |
Upgrade |
|
Buy |
2022-11-09 |
Raymond James |
Upgrade |
|
Outperform |
2022-08-09 |
Morgan Stanley |
Upgrade |
|
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2021-10-25 |
ALEXANDRIA VENTURE INVESTMENTS, L.L.C |
Beneficial Owner of more than 10% of a Class of Security |
166.42K |
Conversion of Exercise of derivative security |
2024-02-07 |
ATLAS VENTURE FUND XI L.P |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2021-12-09 |
BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2021-10-25 |
BAY CITY CAPITAL ,L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2021-10-25 |
FIL, LTD. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
2021-10-25 |
FLYNN JAMES E |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Bain Capital Life Sciences Investors, LLC |
2.81M |
7.35M |
10.19% |
2023-06-29 |
Atlas Venture Life Science Advisors, LLC |
2.76M |
7.23M |
10.02% |
2023-06-29 |
Octagon Capital Advisors LP |
2.42M |
6.35M |
8.81% |
2023-06-29 |
FMR, LLC |
1.91M |
5.00M |
6.93% |
2023-06-29 |
Rivervest Venture Management LLC |
1.44M |
3.78M |
5.23% |
2023-06-29 |
Rock Springs Capital Management, LP |
1.44M |
3.77M |
5.23% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
739.56K |
1.94M |
2.69% |
2023-06-29 |
Vanguard Extended Market Index Fund |
147.85K |
387.36K |
0.54% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
76.08K |
199.33K |
0.28% |
2023-08-30 |
iShares Micro Cap ETF |
41.46K |
118.98K |
0.15% |
2023-05-30 |
Fidelity Extended Market Index Fund |
39.25K |
119.71K |
0.14% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Fund |
34.40K |
90.13K |
0.12% |